Sign up for HER connection

  • HER connection
  • Her connection

    Discover a program designed to support patients with knowledge and information about HER2+ breast cancer.

    Three ways to connect:

  • Receive Updates
    Personalized information to support your treatment

  • Support Line
    Call 866.449.HER2 Nurses available 24/7

  • Online Live Chat
    Nurses available Monday-Friday, 8am EST to 8pm EST.

Join Team HER2

TEAM HER2, launched by Genentech BioOncology in 2010, is the first-ever national walk team dedicated to patients and caregivers affected by HER2-positive breast cancer. TEAM HER2 offers women and caregivers impacted by this diagnosis the opportunity to connect with others within their communities to exchange support and provide motivation.

As a national sponsor of the 2010 Avon Walk for Breast Cancer, Genentech is coordinating TEAM HER2 teams in each of the nine Avon Walk for Breast Cancer events. Everyone affected by HER2-positive breast cancer is invited to join TEAM HER2 to walk in the fight against breast cancer.

The Avon Walk for Breast Cancer is a two-day, 39-mile fundraising walk. By participating in the Avon Walk, you’re helping to raise funds to assist medically under-insured women and men to receive the screening, support, and treatment they require. And leading-edge research teams from around the country will be provided with the funds they need to fuel their quest for a cure.

To apply for Team HER2, interested individuals must first register for the 2010 Avon Walk for Breast Cancer. Avon Walk registration fee and fundraising requirement is the responsibility of the participant.

So, put on your walking shoes, show your support and meet others impacted by HER2-positive breast cancer. Take the first step and join today.


2010 Avon Walk for Breast Cancer - Join Team HER2

Dates City
April 10-11 Houston, TX Register
May 1-2 Washington, D.C. Register
May 15-16 Boston, MA Register
June 5-6 Chicago, IL Register
June 26-27 Rocky Mountains, CO Register
July 10-11 San Francisco, CA Register
September 11-12 Santa Barbara, CA Register
October 16-17 New York, NY Register
October 23-24 Charlotte, NC Register

Who is Herceptin for?

Herceptin is approved for the adjuvant treatment of HER2-overexpressing, node-positive or node-negative (ER/PR-negative or with one high-risk feature)† breast cancer. Herceptin can be used several different ways:

  • As part of a treatment regimen including doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
  • With docetaxel and carboplatin
  • As a single agent following multi-modality anthracycline-based therapy

Herceptin in combination with paclitaxel is approved for the first-line treatment of HER2-overexpressing metastatic breast cancer. Herceptin as a single agent is approved for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease.

† High-risk is defined as ER/PR positive with one of the following features: tumor size >2 cm, age <35 years, or tumor grade 2 or 3.

What important safety information should I know about Herceptin?

Herceptin treatment can result in heart problems, including those without symptoms (reduced heart function) and those with symptoms (congestive heart failure). The risk and seriousness of these heart problems were highest in people who received both Herceptin and a certain type of chemotherapy (anthracycline). Your doctor will stop or strongly consider stopping Herceptin if you have a significant drop in your heart function.

You should be monitored for decreased heart function before your first dose of Herceptin, and frequently during the time you are receiving Herceptin and after your last dose of Herceptin. If you must permanently or temporarily stop Herceptin due to heart problems, you should be monitored more frequently. In one study with Herceptin and certain types of chemotherapy, an inadequate blood supply to the heart occurred.

Some patients have had serious infusion reactions and lung problems; fatal infusion reactions have been reported. In most cases, these reactions occurred during or within 24 hours of receiving Herceptin. Your Herceptin infusion should be temporarily stopped if you have shortness of breath or very low blood pressure. Your doctor will monitor you until these symptoms go away. If you have a severe allergic reaction, swelling, lung problems, inflammation of the lung, or severe shortness of breath, your doctor may need to completely stop your Herceptin treatment.

Worsening of low white blood cell counts associated with chemotherapy has also occurred.

Herceptin can cause low amniotic fluid levels and harm to the fetus when taken by a pregnant woman.

The most common side effects associated with Herceptin were fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, shortness of breath, rash, low white and red blood cells, and muscle pain.

Because everyone is different, it is not possible to predict what side effects any one person will have. If you have questions or concerns about side effects, talk to your doctor.

Please see the Herceptin full Prescribing Information including Boxed WARNINGS and additional important safety information.



Herceptin® (trastuzumab)Herceptin® (trastuzumab)

Adjuvant Care Is defined as additional treatment given after the main treatment plan to decrease the chance of recurrence. Adjuvant therapy for breast cancer can include chemotherapy, hormone therapy, radiation therapy, or biological therapy

Metastatic Breast Cancer Breast cancer that has spread to other sites in the body; also referred to as invasive or infiltrating